Medicine, Hematology Oncology Division

Grants

Grants per year 1995 2007 2008 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2028

• 466 Active
• 1106 Finished

Grants per year

Search results

• Finished

  A Phase III, Open Label, Randomized Study to Assess the Efficacy and Safety of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men with Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment with a New Hormonal

  Hussain, M.

  AstraZeneca Pharmaceuticals LP

  9/26/17 → 1/1/21

  Project: Research project

• Prot #2215-CL-9100: A Multicenter, Open-label Treatment Protocol of Gilteritinib (ASP2215) in Patients with FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3 Mutated AML in Complete Remission (CR) with M

  Frankfurt, O.

  INC Research, LLC, Astellas Pharma Global Development, Inc.

  9/20/17 → 9/20/20

  Project: Research project

• Prot #CA209-703: NU MRFBC 16M05: A Study to Estimate the Anti-Tumor Activity and Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab Followed

  Chandra, S.

  Georgetown University, Bristol-Myers Squibb Company

  9/15/17 → 7/14/20

  Project: Research project

• Prot #SCRX003-001: A Phase 1a/1b Dose Escalation and Expansion Study of Single-Agent SC-003 in Subjects with Platinum-Resistant/Refractory Ovarian Cancer

  Matei, D. E.

  Novella Clinical, LLC, AbbVie Stemcentrx LLC

  9/11/17 → 12/31/20

  Project: Research project

• Prot #1101-HEM-101: A Phase 1 Dose Escalation, Multicenter, Open-label, Safety, Pharmacokinetic and Pharmacodynamic Study of FT-1101 in Patients with Relapsed or Refractory Hematologic Malignancies

  Dinner, S. N.

  Translational Drug Development, LLC, FORMA Therapeutics, Inc.

  9/8/17 → 9/8/20

  Project: Research project

• Executive Officer Grant Agreement

  Dinner, S. N.

  Alliance Foundation Trials, LLC

  9/1/17 → 8/31/19

  Project: Research project

  • Meals 100%
  • Budgets 84%
  • Pharmaceutical Research 52%
  • Telecommunications 51%
  • Triage 41%

• Early Therapeutics and Rare Cancer Vice Chair Role

  Chae, Y. K.

  Oregon Health and Science University, National Cancer Institute

  9/1/17 → 2/28/19

  Project: Research project

  • leadership 100%
  • cancer 85%
  • protocol 75%
  • trial 73%
  • planning 56%

• Prot #13676-01: A Phase 1 Multidose Study To Evaluate The Safety And Tolerability Of XmAb®13676 In Patients With Cd20-Expressing Hematologic Malignancies

  Karmali, R.

  Chiltern International, Inc., Xencor, Inc.

  9/1/17 → 9/1/20

  Project: Research project

• Prot #2003376607: NU JH17U01: Overcoming drug resistance in metastatic castration-resistant prostate cancer with novel combination of TGF-β receptor inhibitor LY2157299 and enzalutamide: a randomized multi-site phase II study

  Hussain, M. & Morgans, A. K.

  Johns Hopkins University

  9/1/17 → 12/31/21

  Project: Research project

• Tissue transglutaminase fibronectin interaction in ovarian cancer stem cells

  Condello, S. & Matei, D. E.

  Northwestern Memorial Hospital

  9/1/17 → 8/31/20

  Project: Research project

  • Neoplastic Stem Cells 100%
  • transglutaminase 2 87%
  • Ovarian Neoplasms 85%
  • Fibronectins 73%
  • Wnt Receptors 47%

• Alliance for Clinical Trials in Oncology Operations Center

  Dinner, S. N.

  Brigham and Women's Hospital, National Cancer Institute

  9/1/17 → 2/28/19

  Project: Research project

  • Budgets 100%
  • Meals 78%
  • Clinical Trials 47%
  • Pharmaceutical Research 41%
  • Telecommunications 40%

• Spherical Nucleic Acids as Therapeutic Vaccines for the Treatment of Prostate Cancer

  Mirkin, C. A., Catalona, W. J., Kuzel, T. M., Lee, A. & Zhang, B.

  Prostate Cancer Foundation

  8/31/17 → 8/30/20

  Project: Research project

  • prostatic neoplasms 100%
  • cancer vaccines 68%
  • nucleic acids 54%
  • antigens 54%
  • immune response 45%

• Subproject for Institution # SP0038706

  Zhang, B.

  Prostate Cancer Foundation

  8/31/17 → 8/30/20

  Project: Research project

  • prostatic neoplasms 100%
  • cancer vaccines 77%
  • antigens 62%
  • immune response 52%
  • animal models 45%

• Prot #NC-6004-004A: A Phase 1b/2 Dose Escalation and Expansion Trial of NC-6004 (Nanoparticle Cisplatin) plus Gemcitabine in Patients with Advanced Solid Tumors or Squamous Non-Small Cell Lung, Biliary Tract, and Bladder Cancer

  Kalyan, A.

  PPD Investigator Services, LLC, NanoCarrier Co., Ltd.

  8/29/17 → 8/29/20

  Project: Research project

• Exploring putative associations between thrombocytopenia and bromodomain modulation

  Crispino, J. D.

  FORMA Therapeutics, Inc.

  8/17/17 → 8/17/18

  Project: Research project

  • Megakaryocytes 100%
  • Thrombocytopenia 52%
  • Apoptosis 16%
  • In Vitro Techniques 12%

• Prot #BP39365: An Open-Label, Multi-Center, Randomized, Dose-Escalation, Phase IB Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281, in Combination with Atezolizumab ± Bevacizumab, Following Obinutuzumab Pre-Treatment, in Pa

  Sosman, J. A.

  INC Research, LLC, Roche TCRC, Inc.

  8/11/17 → 8/11/20

  Project: Research project

• HHMI Medical Research Fellows Program in support of Raul Bhansali

  Crispino, J. D.

  Howard Hughes Medical Institute

  7/24/17 → 7/23/18

  Project: Research project

  • biomedical research 100%
  • research programs 70%
  • education 63%

• The Role of Chaf1b in malignant and normal hematopoiesis

  Crispino, J. D.

  American Society of Hematology

  7/1/17 → 6/30/19

  Project: Research project

  • Chromatin Assembly and Disassembly 100%
  • Hematopoiesis 69%
  • Chromatin 31%
  • Hematopoietic Stem Cells 28%
  • Chromatin Assembly Factor-1 25%

• Prot #MEDI4736-NHL-001: A Phase 1/2, Open Label, Multicenter Study To Assess The Safety And Tolerability Of Durvalumab (Anti-PD-L1 Antibody) As Monotherapy And In Combination Therapy In Subjects With Lymphoma Or Chronic Lymphocytic Leukemia

  Ma, S.

  ICON plc, Celgene International II Sàrl

  6/30/17 → 6/30/20

  Project: Research project

• Fellowship for Roberto Tapia - Minority Medical Student Award Program (MMSAP)

  Crispino, J. D.

  American Society of Hematology

  6/1/17 → 8/31/17

  Project: Research project

  • medical student 100%
  • minority 75%

• 24th Annual Robert H. Lurie Comprehensive Cancer Center Survivor's Walk

  Platanias, L. C.

  Millennium Pharmaceuticals, Inc

  5/25/17 → 5/25/18

  Project: Research project

• Aberrant megakaryopoiesis in the myeloproliferative neoplasms.

  Crispino, J. D.

  National Heart, Lung, and Blood Institute

  5/1/17 → 8/31/20

  Project: Research project

  • Megakaryocytes 100%
  • Primary Myelofibrosis 69%
  • Ribosomes 21%
  • Polycythemia 17%
  • Neoplasms 14%

• Utilization of Clinomic Outcomes, Patient-Derived Xenografts (Avatars), and Next Generation Sequencing Data

  Benson III, A. B.

  Nathan Cummings Foundation

  5/1/17 → 12/31/20

  Project: Research project

  • Heterografts 100%
  • High-Throughput Nucleotide Sequencing 85%
  • Medicine 40%
  • Research Personnel 38%
  • Therapeutics 18%

• Mechanisms of Leukemogenesis in Down Syndrome

  Crispino, J. D. & Zhao, C.

  National Cancer Institute

  5/1/17 → 8/31/20

  Project: Research project

  • Chromosomes, Human, Pair 21 100%
  • Down Syndrome 79%
  • Leukemia, Megakaryoblastic, Acute 59%
  • B-Lymphoid Precursor Cells 45%
  • Chromatin Assembly and Disassembly 44%

• NU UW16B13: A Phase II Study of Neratinib Alone and in Combination with Fulvestrant in Metastatic HER2 Non-amplified but HER2 Mutant Breast Cancer

  Cristofanilli, M.

  Washington University St. Louis, Puma Biotechnology, Inc.

  5/1/17 → 5/1/20

  Project: Research project